Onkológia S3/2018

Pomalidomide in heavily pretreated patient with multiple myeloma: a case report

Objective: The aim of our case report is to show the possibility how to prolong survival of patients with relapsed and refractory multiple myeloma (RRMM) with new antimyeloma drugs. Case report: Here we discuss the case of a heavily pretreated male patient with RRMM who initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally). The patient was previously treated with bortezomib, lenalidomide and carfilzomib and achieved a very good partial remission to pomalidomide-based therapy, which was relatively well tolerated. The therapeutic response was maintained for 12 months. Conclusions: The pomalidomide/dexamethasone regimen resulted in a deeper response compared with three previous regimens. This case illustrates the potential of pomalidomide to overcome lenalidomide refractoriness.

Keywords: relapsed-refractory multiple myeloma, pomalidomide, immunomodulatory drugs